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Abstract
Background: Primary central nervous system lymphoma (PCNSL) may rarely be preceded by “sentinel
demyelination,” a pathologic entity characterized by histologically confirmed demyelinating inflammatory brain
lesions that mimic multiple sclerosis (MS) or acute disseminated encephalomyelitis (ADEM). Interpreting the
overlapping radiologic and clinical characteristics associated with each of these conditions—contrast-enhancing
demyelination of white matter and relapsing and remitting steroid-responsive symptoms respectively—can be a
significant diagnostic challenge.
Case presentation: We describe a 57-year-old woman with an unusual clinical course who presented with
multi-focal enhancing white matter lesions demonstrated to be inflammatory demyelination by brain biopsy.
Despite a good initial response to steroids and rituximab for treatment of presumed tumefactive multiple sclerosis,
the patient’s condition rapidly deteriorated, and a repeat brain biopsy six months later was consistent with a
diagnosis of diffuse large B-cell lymphoma.
Conclusions: Early clinical suspicion for PCNSL and awareness that biopsied lesions may initially show sentinel
demyelination suggestive of alternate diagnoses may be essential for early initiation of appropriate therapies and
mitigation of disease progression. Clinical, pathophysiological, and diagnostic aspects of sentinel demyelination and
PCNSL are discussed.
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Background
Primary central nervous system lymphomas (PCNSL)
are rare neoplasms that account for less than 1 % of all
brain tumors [1, 2]. Though more common in the set-
ting of immunosuppression, the incidence of PCNSL has
increased in the last three decades among immunocom-
petent individuals [1–4]. PCNSLs are most frequently
diffuse large B-cell non-Hodgkin lymphomas, represent
4 % of intracranial neoplasms, and present at a median
age of 60 [5]. Surface expression of both BCL6 and
IRF4, along with immunoglobulin gene rearrangement
in the majority of PCNSL B-cells indicate that the tumor
cells have an activated B-cell phenotype [6].
PCNSL rarely presents with steroid-responsive, multi-
focal demyelinating “sentinel” lesions characterized by a
predominance of T-cell infiltrates and few B-cells [1–4].
These demyelinating brain lesions may be histologically
indistinguishable from those seen in multiple sclerosis
(MS). Because both MS and PCNSL may present with
* Correspondence: robert.k.shin@gunet.georgetown.edu
Mark D. Kvarta and Deva Sharma are co-first authors.
†Equal contributors
8Department of Neurology, MedStar Georgetown University Hospital, District
of Columbia, Washington, USA
Full list of author information is available at the end of the article
© 2016 Kvarta et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kvarta et al. BMC Neurology  (2016) 16:72 
DOI 10.1186/s12883-016-0596-1
contrast-enhancing white matter lesions and relapsing
and remitting symptoms and signs that improve with
steroid therapy, this can lead to diagnostic confusion. Bi-
opsy of these sentinel lesions early in the course of dis-
ease, even months before PCNSL is ultimately
diagnosed, can lead to diagnostic confusion, especially in
the setting of preceding corticosteroid administration [1,
2, 7, 8].
Here we describe a case of a steroid-responsive,
histologically-confirmed inflammatory demyelinating le-
sion which proved later to be a rapidly progressing
PCNSL diagnosed on repeat biopsy. We offer guidelines
to the approach to a brain biopsy in older adults, to fa-
cilitate increased diagnostic accuracy.
Case presentation
In October 2009, a previously healthy 57-year-old
woman presented with a six week history of progressive
fatigue, confusion and headache associated with a right
inferior homonymous quadrantanopsia. The patient re-
ported frequently bumping into objects as well as several
recent falls. She denied alcohol or drug use and was not
taking any prescribed medications. Physical exam re-
vealed a mild right hemiparesis and a wide-based gait, in
addition to the visual field defect. There was no relevant
past medical, family, or psychosocial history. The pa-
tient’s clinical timeline is summarized in Table 1.
A brain MRI revealed multiple enhancing lesions, in-
cluding right frontal and left parieto-occipital mass le-
sions, that are nonspecific but concerning for
demyelination, an infectious or inflammatory process, or
neoplasm (Fig. 1).
Following pre-operative corticosteroid treatment
(dexamethasone 6 mg IV q6h for 3 days), the left
parieto-occipital lesion was biopsied (Fig. 2), revealing
mononuclear infiltrates with numerous T cells (CD3+),
histiocytes (CD68+), and a few scattered B cells (CD20
+). There was no cytological evidence of malignancy,
and axonal preservation was evident, consistent with de-
myelination. TAF, GMS, AFB and FITE stains did not
demonstrate any microorganisms. In addition, HSV 1
and 2 immunohistochemistry, EBV in-situ hybridization
and HIV serologies were negative.
The patient was diagnosed with acute multi-focal de-
myelination, presumed to be acute disseminated enceph-
alomyelitis or tumefactive multiple sclerosis, and treated
with intravenous corticosteroids. She improved rapidly
but shortly after discharge developed worsening right-
sided weakness and dysarthria and returned several
weeks later. At that time, she was alert but mildly disor-
iented, with intact sensation to temperature, pinprick




A 57 year-old woman with no significant past medical history presents with 6 weeks of fatigue, confusion and headache, with
physical exam revealing right inferior homonymous quadrantanopsia, mild right hemiparesis and a wide-based gait admitted for
evaluation of multiple brain lesions
Brain MRI revealed multiple enhancing lesions, including right frontal and left parieto-occipital mass lesions concerning for
neoplasm
Patient was treated with pre-operative corticosteroids for 3 days
October 28 Biopsy of the left parieto-occipital lesion revealed mononuclear infiltrates with evidence of demyelination, but without evidence
of malignancy
Patient was treated with a second round of intravenous corticosteroids for presumed acute disseminated encephalomyelitis or
tumefactive multiple sclerosis
Patient was discharged home after showing rapid clinical improvement
November 23 Over the course of several weeks, the patient developed progressive dysarthria and right-sided weakness, prompting readmission
to the hospital
A repeat brain MRI showed an increase in the size of the left-sided lesions, with vasogenic edema and subfalcine herniation
November 25 Patient refused a repeat brain biopsy
November 27 Patient was treated with a third round of intravenous corticosteroids and rituximab infusions, resulting in symptomatic
improvement and discharge from the hospital
April 13, 2010 Over the following five months, after initial improvement, the patient again developed progressively worsening right hemiparesis
and dysarthria, resulting in a second hospital readmission
MRI of the brain showed enlargement of the prior intracranial lesions with nodular enhancement suggestive of neoplasm
May 25 A second brain biopsy of the left parietal lesion was consistent with diffuse large B-cell lymphoma
Patient was treated with high dose methotrexate and leucovorin
June 7 In light of her continued clinical deterioration despite treatment, the patient was transferred to hospice care
Patient passed away in hospice care
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and vibration, brisk deep tendon reflexes throughout,
and bilateral ankle clonus. Gait again was wide-based
and unsteady.
Repeat MRI showed decreased edema and enhance-
ment of the right-sided lesions, but an increase in the
size of the left-sided lesions with vasogenic edema and
subfalcine herniation (Fig. 3). The patient refused a re-
peat brain biopsy. The symptoms, signs and radiographic
lesions improved with a second course of intravenous
corticosteroids and four weekly rituximab infusions. She
remained clinically stable for the next five months, but
was ultimately hospitalized for a third time with worsen-
ing right hemiparesis and dysarthria. MRI showed en-
largement of the prior intracranial lesions with nodular
enhancement strongly suggestive of a neoplasm (Fig. 4).
PET-CT scan revealed increased metabolism within the
brain lesions without evidence of extracranial malig-
nancy. A second brain biopsy of the left parietal lesion
was obtained through the previous burr hole. Six
months after the first biopsy of the same lesion, the sec-
ond biopsy revealed markedly different histopathologic
results (Fig. 5), including large, perivascular malignant
lymphoid cells uniformly positive for CD20 with a
smaller number of CD3+ mature T cells – consistent
with diffuse large B-cell lymphoma. Despite treatment
with high-dose methotrexate and leucovorin, the pa-
tient’s condition deteriorated. She was transferred to a
hospice care facility and died several days later.
Discussion
As this case demonstrates, PCNSL may be preceded by
demyelinating lesions [1–4, 7] suggestive of tumefactive
multiple sclerosis or ADEM. PCNSL may mimic MS
with waxing and waning brain lesions; PCNSL symp-
toms and signs are generally responsive to corticoste-
roids [1]. Although MS is typically characterized by
multiple small demarcated plaques, tumefactive MS and
other atypical forms of MS can present radiologically as
space-occupying lesions with mass effect and edema re-
sembling brain tumors [9]. In this patient, two brain bi-
opsies from the same location yielded significantly
different results. The first revealed numerous CD3+ in-
filtrates, scattered CD20+ immunoreactive cells, and
axonal sparing and demyelination without evidence of a
neoplasm. The second biopsy revealed large malignant
perivascular lymphoid cells and a striking increase in
CD20+ immunoreactivity diagnostic of PCNSL. How did
two biopsies of the same lesion, separated only by
months, yield such different histopathological results?
Randomly coincidental findings
Could the co-existence of “sentinel demyelination” and
PCNSL be simply coincidental and unrelated patholo-
gies? Pure coincidence has been hypothesized when MS
and PCNSL have been found in two different locations
in the same patient separated in time by many years
[10]. In our case, however, both pathologies were found
within the same lesion within a six month time interval,
making coincidence seem less likely.
Missed first biopsy
Is it possible that the first biopsy missed the "true" lesion
harboring malignant B-cell clones? If so, how do we ex-
plain the presence of inflammatory demyelination? A
paraneoplastic phenomenon is possible, as anti-MOG
antibodies were found in the sera of a patient with senti-
nel demyelinating lesions preceding PCNSL [2]. These
Fig. 1 Brain MRI (October 2009): axial FLAIR (left) and axial T1 post
contrast (right) revealing right frontal and left parieto-occipital
enhancing lesions with surrounding edema
Fig. 2 Histopathology (October 2009): H&E 60x showing reactive perivascular astrocytosis and macrophages (left), CD68 60x immunostain for
histiocytes (center), NF 180x showing relative preservation of axons (right)
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may have been produced by a monocolonal population
of transformed B-cells, promoting autoimmune demye-
lination. Although considerable T-cell infiltration is seen
in PCNSL [11], a halo of T-cell infiltration and demye-
lination surrounding lymphoma has never been de-
scribed to our knowledge.
Malignant transformation during latent period
Could tumefactive demyelination have transformed
into B-cell lymphoma [2]? In our patient, the radio-
graphic appearance of the lesion changed in conjunc-
tion with the biopsy results, suggesting that the lesion
itself may have histologically evolved. It has been hy-
pothesized that lymphocytes may become entrapped
in the brain following an inflammatory response and
may later undergo malignant transformation [2, 12].
However, patients with inflammatory diseases of the
CNS have not been shown to have an increased inci-
dence of PCNSL [13], although there is a well-
described increased incidence of lymphoma in pa-
tients with systemic inflammatory diseases [14].
Disruption of anti-tumor immune response by
corticosteroids
Could the T-cell infiltrates in the initial biopsy have rep-
resented a cell-mediated immune response against the
lymphoma, thereby masking a diagnosis of PCNSL [4,
11]? This hypothesis would predict that when the host
immune system is disrupted by intermittent or pro-
longed corticosteroid therapy, a “suppressed” neoplastic
B-cell clone could emerge from lymphocytic infiltrates
[15].
The observation that the presence of non-malignant
infiltrates consisting predominantly of T-cells correlates
with improved survival in follicular lymphoma and re-
ports of spontaneous regression of lymphoma in im-
munocompetent individuals support the existence of a
suppressive cell-mediated anti-tumor response [16–18].
Masking of diagnosis by corticosteroids
Did treatment with corticosteroids mask the presence of
malignant B cells? Many B-cell lymphomas, including
PCNSL, are steroid-responsive [2–4, 17, 19, 20], whereas
activated T-cells may be relatively protected from
glucocorticoid-induced apoptosis [11, 17]. Selective sur-
vival of a few steroid-resistant B-cell clones following
corticosteroid administration could explain the “missing”
B-cells on the initial biopsy, diminishing steroid respon-
siveness over time, and ultimately, the emergence of
steroid-resistant B-cell infiltrates on repeat biopsy. A re-
cent retrospective study examining approximately 1000
cases of PCNSL suggested that the effects of corticoster-
oid treatment preceding biopsy rendered accurate diag-
nosis from biopsy impossible in up to 50 % of cases [8].
Differentiating between demyelination and CNS
lymphoma
Summarizing 15 cases from the literature, combined
with our own case presentation, Table 2 details patient
demographics and presenting signs and symptoms of pa-
tients who were initially suspected of a demyelinating
Fig. 5 Histopathology (May 2010): H&E 180x showing large
malignant perivascular lymphoid cells (left), CD20 180x pan B-cell
immunostain (right)
Fig. 3 Brain MRI (November 2009): axial FLAIR (left), axial T1 post
contrast (right) demonstrating an increase in the size of the left-sided
lesions, vasogenic edema, and mass effect leading to subfalcine
herniation (notice left parietal burr hole from the biopsy)
Fig. 4 Brain MRI (April 2010): axial FLAIR (left), axial T1 post contrast
(right) reveal progression of nodular enhancement of the persisting
left-sided lesions
Kvarta et al. BMC Neurology  (2016) 16:72 Page 4 of 7
disease but were later diagnosed with primary CNS
lymphoma.
While each patient presentation is unique, there are
some clinical “red flags” that should increase suspicion for
PCNSL (Table 3). Examples include worsening in radio-
graphic appearance of brain lesions over time, deteriorat-
ing clinical course despite adequate treatment for
demyelinating disease, sustained clinical dependence on
corticosteroids (which is unusual in MS) [21], and ad-
vanced age. On average, it has previously been reported
that immunocompetent patients with PCNSL present be-
tween the ages of 55–70, while patients with MS and
ADEM most frequently present in young adulthood and
childhood respectively [22]. In addition, older patients
with MS are more likely to have spinal cord involvement
(80 % in MS vs. <2 % in PCNSL) and CSF oligoclonal
bands (98 % in MS vs. only 27 % in PCNSL) when com-
pared to patients with PCNSL [7].
Barkhof and modified McDonald criteria can be used
to predict the risk of progression from a clinically iso-
lated syndrome (CIS) or ADEM to MS [23, 24]. Identify-
ing the predictive value of spatial distribution criteria for
the development of PCNSL from a single sentinel demye-
linating event would be extremely relevant and may shed
further light on the pathophysiology of this disease pro-
gression. In our patient, lesions involved posterior frontal
deep white matter, the left parietal lobe, and bilateral oc-
cipital lobe with callosal involvement. MS lesions are com-
mon in these areas. ADEM lesions also include
periventricular and subcortical white matter, and often in-
volve corpus callosum, thalamus, and basal ganglia [24].
Discerning radiologically between these entities will re-
main challenging without identification of more specific
patterns of imaging findings.
Thorough approaches to both radiographic and histo-
pathologic differential diagnoses in such cases have been
detailed elsewhere [19, 20, 25]. Radiographically tumefactive
MS is frequently associated with ring- or heterogenous en-
hancement, with features of varying levels of enhancement
and pallor reflecting evolution of lesions over time. How-
ever, ring, homogenous and heterogenous gadolinium pat-
terns have all been observed in large case series [26]. Ring-
enhancement and T1-hypointensities (‘black holes’) are as-
sociated with persistence and severity [27–30]. PCNSL, in
contrast, is most commonly diffusely enhancing due to lack
of central necrosis [19], as in this patient’s early images.
If a brain biopsy is being considered in this context of
initial diagnostic workup, steroids should be withheld,
unless rapid neurological deterioration is present, as
most patients with PCNSL tolerate deferral of steroid
therapy as long as biopsy is performed in a timely man-
ner [20]. However, if steroid treatment has already been
initiated and MRI is consistent with lymphoma, empir-
ical treatment for PCNSL in the absence of histopatho-
logic confirmation of disease may be cautiously
considered, as withdrawal of steroids with plans for re-
biopsy has often resulted in poor patient prognosis and
rapid death [31].
Conclusions
This case serves as a reminder that PCNSL can be pre-
ceded by sentinel lesions indistinguishable from the demye-
lination of MS or ADEM, and that steroid treatment before
biopsy obscures a diagnosis of PCNSL. Clinicians must be
vigilant to realize that not all histologic and radiologic evi-
dence of demyelination correspond to a primary demyelin-
ating disease. It is important to maintain a high level of
Table 2 16 patients with evidence of demyelination, ultimately
diagnosed with CNS lymphoma
Mean Age 46.2 (range 20–65)
Female:Male 12:4
Initial response to steroids 16/16 (100 %)





Hemiparesis 50 % *
Visual symptoms (diplopia, anopsia
or visual field cut, nystagmus)
50 % *
Cognitive (memory, concentration, confusion) 50 % *
Ataxia or gait disturbance 40 % *
Dysarthria 31.3 % *
Headache 31.3 % *
Fatigue or somnolence 25 % *
Vertigo 25 %







*-our patient (Cases referenced: [1, 2, 4, 10, 14, 22, 33–37])
Table 3 Criteria which should raise clinical suspicion for PCNSL
and sentinel demyelination in patients with white matter lesions
Clinical • Middle to older age with no prior clinical
episodes or radiographic lesions suggestive of MS
• Rapidly deteriorating course
• Steroid dependence
• Lack of spinal cord involvement
Imaging • Increased enhancement or lesion size over time
• Disproportionate mass effect
CSF • Abnormal cytology (clonal IgG gene rearrangement)
• No oligoclonal bands
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suspicion for PCNSL to facilitate early diagnosis and treat-
ment, particularly with specific clinical and diagnostic fea-
tures (Table 3). The combination of chemotherapy and
radiotherapy has significantly improved prognosis for pa-
tients with PCNSL, leading to prolonged survival and even
cure in some cases [21, 32]. Hence, early diagnosis of
PCNSL will ultimately lead to more timely therapeutic in-
terventions. Finally, we would recommend discretion in the
use of corticosteroids prior to biopsy in patients in whom
PCNSL is suspected.
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